SciClone and APR have entered into a licensing agreement granting SciClone the commercialization rights for APR’s anti-nausea drug – ondansetron RapidFilm for China and Vietnam. Ondansetron RapidFilm is
SuperGen has reported a net loss $2.4 million for the second quarter of 2009 , or $0.04 per basic and diluted share, as compared to a net loss
SpePharm has launched MuGard in Norway. The company’s new move follows previous commercial launches in the UK, Germany, Italy and Greece. Under a license from Access, SpePharm is
Insmed, a biopharmaceutical company, will cease the supply of IPLEX to any new patients. In addition, the company will not initiate further clinical trials with IPLEX at this
Amgen and GlaxoSmithKline (GSK) would collaborate to share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico, once the product
AVI and Action Duchenne have signed a collaboration agreement to support the acceleration of R&D for AVI’s exon skipping candidate drugs, for the treatment of DMD. The agreement
Takeda has filed a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare, for a fixed-dose combination tablet of Actos with sulfonylurea. The drug
Avila has entered into an option agreement with Novartis to develop novel covalent drug program from Avila’s research pipeline, in combination with an equity investment. The agreement includes
Cryo-Cell has announced a research and development collaboration agreement with Cryopraxis Cryobiology. Reportedly, the partnership would allow Cryopraxis to conduct clinical studies using Cryo-Cell’s proprietary C’elle menstrual stem
Oncolytics has completed an initial 100-litre production run of REOLYSIN under cGMP conditions with the support of its contract manufacturer, SAFC Pharma. The company is now preparing for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.